Clinical Updates
Drug approvals, guideline changes, and treatment advances
Biotech Industry Faces Political Uncertainty and AI Profitability Questions at BIO 2026
Biotech executives at BIO 2026 confronted mounting concerns over Chinese competition, the uncertain profitability of AI-driven drug discovery, and political…
Editor's Top Picks
Eli Lilly’s Obesity Drug Access: What We Know About FDA Approval Pathways
Regulatory pathways and corporate strategy shape early access to obesity drug candidates. Pharmaceutical acquisitions in the metabolic disease sector reflect…
Submit Your Paper →
More form Clinical Updates
Congenital Syphilis Surging in U.S.: A Physician’s Urgent Call for Action
Congenital syphilis rates in the United States are rising sharply, alarming physicians and public health…
Diabetes and Dementia: New Evidence Reveals Bidirectional Risk and Potential Neuroprotection
Mounting evidence reveals that diabetes and dementia share bidirectional pathophysiological pathways involving impaired glucose metabolism,…
Digital health tools increase physical activity in heart disease patients, meta-analysis shows
A meta-analysis published in the Journal of the American Heart Association confirms that smartphone apps…
Personalized Cartilage Grafts Offer New Hope for Infants with Life-Threatening Airway Narrowing
Researchers at Children's Hospital of Philadelphia have developed personalized cartilage grafts using decellularized scaffolds and…
Beyond GLP-1 drugs: Why obesity care requires more than medication
GLP-1 medications like semaglutide and tirzepatide have transformed obesity treatment, yet leading specialists warn that…